Wave Life Sciences - WVE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $22.22
  • Forecasted Upside: 45.53%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 1 Strong Buy Ratings
$15.27
▲ +0.83 (5.75%)

This chart shows the closing price for WVE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Wave Life Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for WVE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for WVE

Analyst Price Target is $22.22
▲ +45.53% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Wave Life Sciences in the last 3 months. The average price target is $22.22, with a high forecast of $36.00 and a low forecast of $15.00. The average price target represents a 45.53% upside from the last price of $15.27.

This chart shows the closing price for WVE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 10 investment analysts is to buy stock in Wave Life Sciences. This rating has held steady since October 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/16/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/14/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/13/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/12/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/10/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/8/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/7/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/7/2024

Latest Recommendations

  • 1 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/21/2024MizuhoBoost TargetOutperform ➝ Outperform$19.00 ➝ $22.00
11/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
11/12/2024Truist FinancialBoost TargetBuy ➝ Buy$17.00 ➝ $36.00
11/4/2024B. RileyBoost TargetBuy ➝ Buy$19.00 ➝ $22.00
10/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
10/21/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$7.00 ➝ $15.00
10/17/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$13.00 ➝ $17.00
10/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
10/16/2024Leerink PartnersBoost TargetOutperform ➝ Outperform$20.00 ➝ $22.00
10/16/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$11.00 ➝ $22.00
10/16/2024Raymond JamesUpgradeOutperform ➝ Strong-Buy$13.00 ➝ $22.00
10/4/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$5.00 ➝ $7.00
10/3/2024B. RileyBoost TargetBuy ➝ Buy$11.00 ➝ $19.00
9/27/2024JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$10.00 ➝ $13.00
9/25/2024HC WainwrightBoost TargetBuy ➝ Buy$15.00 ➝ $22.00
9/19/2024B. RileyInitiated CoverageBuy$11.00
9/9/2024JPMorgan Chase & Co.Initiated CoverageOverweight$10.00
6/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
6/25/2024MizuhoReiterated RatingOutperform ➝ Outperform$19.00 ➝ $19.00
5/15/2024Wells Fargo & CompanyInitiated CoverageOverweight$11.00
4/1/2024Truist FinancialReiterated RatingBuy ➝ Buy$17.00
3/7/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$5.00
3/7/2024HC WainwrightBoost TargetBuy ➝ Buy$8.00 ➝ $15.00
12/19/2023Leerink PartnrsUpgradeMarket Perform ➝ Outperform
12/19/2023Leerink PartnersUpgradeMarket Perform ➝ Outperform$5.00 ➝ $12.00
8/4/2023Leerink PartnrsReiterated RatingMarket Perform
8/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$8.00
7/5/2023Raymond JamesInitiated CoverageOutperform$7.00
5/24/2023MizuhoLower Target$13.00 ➝ $10.00
5/23/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$7.00 ➝ $5.00
4/14/2023MizuhoReiterated RatingBuy$13.00
3/23/2023HC WainwrightReiterated RatingBuy$8.00
12/14/2022Leerink PartnersBoost TargetMarket Perform$2.00 ➝ $7.00
11/11/2022Royal Bank of CanadaLower TargetSector Perform$8.00 ➝ $5.00
10/24/2022Leerink PartnersReiterated RatingMarket Perform
5/13/2022HC WainwrightLower Target$10.00 ➝ $8.00
3/4/2022HC WainwrightReiterated RatingBuy$10.00
9/29/2021HC WainwrightReiterated RatingBuy$10.00
5/19/2021MizuhoBoost TargetBuy$7.00 ➝ $8.00
3/30/2021Truist FinancialLower Target$27.00 ➝ $17.00
3/30/2021Leerink PartnersLower TargetMarket Perform$10.00 ➝ $7.00
3/30/2021MizuhoLower TargetBuy$21.00 ➝ $7.00
3/30/2021Royal Bank of CanadaLower TargetSector Perform$13.00 ➝ $8.00
3/11/2021MizuhoBoost TargetBuy$19.00 ➝ $21.00
3/7/2021Royal Bank of CanadaReiterated RatingHold
3/7/2021Leerink PartnersReiterated RatingHold$10.00
12/15/2020HC WainwrightReiterated RatingBuy$20.00
11/20/2020MizuhoLower TargetBuy$21.00 ➝ $19.00
10/22/2020Royal Bank of CanadaInitiated CoverageSector Perform$13.00
9/22/2020Truist FinancialBoost Target$20.00 ➝ $27.00
6/7/2020MizuhoReiterated RatingBuy$21.00
1/2/2020HC WainwrightLower TargetBuy$33.00 ➝ $20.00
12/31/2019SunTrust BanksReiterated RatingBuy$20.00
12/31/2019Leerink PartnersDowngradeOutperform ➝ Market Perform$33.00 ➝ $10.00
12/30/2019MizuhoInitiated CoverageBuy$65.00
12/17/2019SunTrust BanksLower TargetBuy$39.00 ➝ $27.00
12/17/2019GuggenheimLower TargetBuy$43.00 ➝ $25.00
12/16/2019MizuhoInitiated CoverageBuy$65.00
12/16/2019CowenReiterated RatingHold
(Data available from 12/7/2019 forward)

News Sentiment Rating

1.05 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/11/2024
  • 5 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/10/2024
  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/10/2024
  • 3 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
8/9/2024
  • 6 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/8/2024
  • 18 very positive mentions
  • 21 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/8/2024
  • 16 very positive mentions
  • 25 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/7/2024
  • 20 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/7/2024

Current Sentiment

  • 20 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Wave Life Sciences logo
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Read More

Today's Range

Now: $15.27
Low: $14.52
High: $15.67

50 Day Range

MA: $13.18
Low: $8.00
High: $16.44

52 Week Range

Now: $15.27
Low: $3.50
High: $16.74

Volume

735,804 shs

Average Volume

1,172,053 shs

Market Capitalization

$2.33 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Wave Life Sciences?

The following equities research analysts have issued stock ratings on Wave Life Sciences in the last twelve months: B. Riley, HC Wainwright, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Mizuho, Raymond James, Royal Bank of Canada, StockNews.com, Truist Financial Co., and Wells Fargo & Company.
View the latest analyst ratings for WVE.

What is the current price target for Wave Life Sciences?

0 Wall Street analysts have set twelve-month price targets for Wave Life Sciences in the last year. Their average twelve-month price target is $22.22, suggesting a possible upside of 45.5%. Truist Financial Co. has the highest price target set, predicting WVE will reach $36.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $15.00 for Wave Life Sciences in the next year.
View the latest price targets for WVE.

What is the current consensus analyst rating for Wave Life Sciences?

Wave Life Sciences currently has 1 hold rating, 8 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe WVE will outperform the market and that investors should add to their positions of Wave Life Sciences.
View the latest ratings for WVE.

What other companies compete with Wave Life Sciences?

How do I contact Wave Life Sciences' investor relations team?

Wave Life Sciences' physical mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company's listed phone number is (656) 236-3388 and its investor relations email address is [email protected]. The official website for Wave Life Sciences is www.wavelifesciences.com. Learn More about contacing Wave Life Sciences investor relations.